Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, March 27, 2024 -- Revive Therapeutics Ltd. , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...

Related Keywords

Canada ,Toronto ,Ontario ,United States ,Canadian ,American ,David Cutler ,Michael Frank ,Therapeutics Ltd ,Harvard University ,Us Food Drug Administration ,Regulation Services Provider ,Neither The Canadian Securities Exchange ,Drug Administration ,About Revive Therapeutics ,Emergency Use Authorization ,Orphan Drug ,Fast Track ,Breakthrough Therapy ,Canadian Securities Exchange ,Five American Adults Who Have Had ,